Washington, DC — Yesterday, the Centers for Medicare and Medicaid Services made a final decision to limit coverage of Biogen’s Alzheimer’s drug, Aduhelm. Last year, Biogen set the price of Aduhelm at $56,000 despite mixed clinical trial results and limited benefits for patients. If Medicare were to broadly cover the drug, it would raise premium costs for millions of seniors. In response, Protect Our Care Chair Leslie Dach issued the following statement:
“Despite intense lobbying by Big Pharma and their front groups, CMS made the right decision to limit Adhelm coverage. Big drug companies should not be cashing in at the expense of millions of seniors struggling to afford their everyday health costs. In addition to being unproven and potentially dangerous for patients, Adhulem is exorbitantly expensive and remains an example of why we need to pass prescription drug reform immediately.”